Iovance Biotherapeutics vs its peers
The 10 largest Biotechnology companies by market value, prices of Nov 20, 2026
Iovance Biotherapeutics is the 10th largest of the 10 biggest Biotechnology companies on OQRO by market value, at $3.19B. Its revenue of $264M in fiscal 2025 ranks 10th of 10. It runs at an operating loss of 153% of revenue, against a group median margin of 29%. Revenue grew 61% on the year before, against a median of +8.0%.
Side by side
| Company | Market value | Revenue | Growth y/y | 5-yr growth / yr | Gross margin | Operating margin | Net margin | Free cash flow margin | R&D / revenue | Price / earnings | Price / sales | FCF yield | Stock, 12 months |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AmgenAMGN · FY2025 | $236B | $36.8B | +10.0% | +7.6% | 67.2% | 24.7% | 21.0% | 22.0% | 19.8% | 30.6x | 6.4x | 3.4% |
Each company’s latest fiscal year (FY), so the years can end a few months apart. Price ratios divide today’s market value by that year’s figure; price / earnings is left out on a loss. “—” means the company did not tag that line in its annual report.
Operating margin
- UTHR47%
- EXEL38%
- VRTX35%
- GILD34%
- INCY29%
- REGN25%
- AMGN25%
- IOVA−153%
- MRNA
Compare Iovance Biotherapeutics head to head
Where Iovance Biotherapeutics’s revenue comes from and where it goes: Iovance Biotherapeutics revenue breakdown. Twenty years of results: Iovance Biotherapeutics financial history.
Common questions
Who are Iovance Biotherapeutics's competitors?
The largest companies in its industry (Biotechnology) by market value: Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Moderna (MRNA), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY) and Exelixis (EXEL). They share Iovance Biotherapeutics's industry listing; not every one competes with it on every product.
Is Iovance Biotherapeutics bigger than Amgen?
No, by market value: Iovance Biotherapeutics is worth $3.19B and Amgen $236B. By revenue, Iovance Biotherapeutics brought in $264M in fiscal 2025 and Amgen $36.8B in fiscal 2025.
How does Iovance Biotherapeutics's valuation compare with its peers?
Where these figures come from
The group is the companies OQRO lists in the same industry as Iovance Biotherapeutics (Biotechnology), the largest 9 by market value, plus Iovance Biotherapeutics. Companies whose latest annual report is more than a year and a half old, or that report in a currency other than the dollar, are left out.
Revenue, operating income, net income, gross profit, research and development and free cash flow (cash from operations minus capital expenditure) are each company’s own full-year lines from its latest 10-K, as tagged in XBRL (SEC companyfacts). Market value is the last close times the shares outstanding on the latest filing. Price / earnings is market value over net income; price / sales is market value over revenue; free cash flow yield is free cash flow over market value. Five-year growth is the yearly rate that takes revenue from five fiscal years before to the latest. This page describes the past and is not investment advice. No language model wrote it.









